Vericel (VCEL)
(Real Time Quote from BATS)
$46.12 USD
-0.45 (-0.97%)
Updated Sep 23, 2024 01:34 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Price, Consensus and EPS Surprise
VCEL 46.12 -0.45(-0.97%)
Will VCEL be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for VCEL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VCEL
What Makes Vericel (VCEL) a New Strong Buy Stock
Vericel Corporation (VCEL) Reports Q2 Loss, Lags Revenue Estimates
VCEL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vericel Corporation (VCEL) Q4 Earnings Beat Estimates
Inhibrx, Inc. (INBX) Reports Q4 Loss, Tops Revenue Estimates
Are You Looking for a Top Momentum Pick? Why Vericel Corporation (VCEL) is a Great Choice
Other News for VCEL
Vericel (VCEL) Shares Cross Below 200 DMA
Vericel to Present at the Morgan Stanley Global Healthcare Conference on Friday, September 6, 2024
Buy Rating for Vericel on FDA Approval and Market Expansion Potential
Vericel’s Strategic Advancements Prompt Buy Rating: Expanding Market Reach with FDA-Approved MACI Arthro
Buy Rating Affirmed for Vericel Amidst FDA Approval and Promising MACI Arthro Launch